AcuCort

After consultation with the company’s largest shareholders in terms of votes, as of September 30 2025, the nomination committee consists of the following members:

•    Sarah Fredriksson, Aqilion AB, Chair of the nomination committee 
•    Anne-Charlotte Poulsen, Life Science Investment Fund (LSIF)
•    Tomas Nilsson, representing Jonas Jönmark, CEO of AcuCort
The 2026 Annual General Meeting will be held in Lund. The exact date will be announced in the notice convening the meeting. The Nomination Committee’s proposals will be presented in the notice and on the company’s website.

For further information: 
Ebba Fåhreus, styrelsens ordförande 
Telefon: 073 400 04 33
Epost: ebba@smileincubator.life

About AcuCort AB (publ)
AcuCort has developed and is commercializing Zeqmelit®, a new rapidly dissolving oral film placed on the tongue, based on the well-known cortisone substance dexamethasone. The drug is a smart product in a new, innovative, patented, and user-friendly administration form primarily for the treatment of severe and acute allergic reactions, croup in children, nausea and vomiting during chemotherapy, and for the treatment of patients with COVID-19 requiring supplemental oxygen therapy. Zeqmelit® is approved in Sweden, Denmark, Norway, and Finland. AcuCort (ticker: ACUC) is listed on the Spotlight Stock Market. Visit www.acucort.se for more information.